Lawren Vandevrede, MD, PhD

Behavioral Neurology Clinical Fellow
+1 415 353-2057
Fields of Interest: 

As a fellow in the Behavioral Neurology Training Program at UCSF, Dr. Lawren Vandevrede's overarching goal is to provide outstanding clinical care to patients with dementia and their caregivers. He completed his medical training in Chicago, where he also obtained a PhD degree in neuroscience working with his mentor to develop novel therapeutic agents for the treatment of Alzheimer’s disease. He completed his intern year in medicine at the Massachusetts General Hospital, and most recently, he finished his residency in neurology at Partners HealthCare in Boston. His clinical and research interests are in advancing the care of patients with neurodegenerative disorders, either through development of novel therapeutics or increasing our understanding of the disease process.

Publications: 

Symptomatic amyloid-related imaging abnormalities in an APOE e4/e4 patient treated with aducanumab.

Alzheimer's & dementia (Amsterdam, Netherlands)

VandeVrede L, Gibbs DM, Koestler M, La Joie R, Ljubenkov PA, Provost K, Soleimani-Meigooni D, Strom A, Tsoy E, Rabinovici GD, Boxer AL

Four-Repeat Tauopathies: Current Management and Future Treatments.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

VandeVrede L, Ljubenkov PA, Rojas JC, Welch AE, Boxer AL

Targeting tau: Clinical trials and novel therapeutic approaches.

Neuroscience letters

VandeVrede L, Boxer AL, Polydoro M

Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.

Movement disorders clinical practice

VandeVrede L, Dale ML, Fields S, Frank M, Hare E, Heuer HW, Keith K, Koestler M, Ljubenkov PA, McDermott D, Ohanesian N, Richards J, Rojas JC, Thijssen EH, Walsh C, Wang P, Wolf A, Quinn JF, Tsai R, Boxer AL

Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy.

JAMA neurology

Mantyh WG, Spina S, Lee A, Iaccarino L, Soleimani-Meigooni D, Tsoy E, Mellinger TJ, Grant H, Vandevrede L, La Joie R, Lesman-Segev O, Gaus S, Possin KL, Grinberg LT, Miller BL, Seeley WW, Rabinovici GD

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Nature medicine

Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, VandeVrede L, Chai X, Proctor NK, Airey DC, Shcherbinin S, Duggan Evans C, Sims JR, Zetterberg H, Blennow K, Karydas AM, Teunissen CE, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Rabinovici GD, Dage JL, Rojas JC, Boxer AL

Erratum to: A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.

Molecular neurodegeneration

Luo J, Lee SH, VandeVrede L, Qin Z, Aissa MB, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR

A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.

Molecular neurodegeneration

Luo J, Lee SH, VandeVrede L, Qin Z, Ben Aissa M, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR

Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.

BMC neuroscience

Luo J, Lee SH, VandeVrede L, Qin Z, Piyankarage S, Tavassoli E, Asghodom RT, Ben Aissa M, Fà M, Arancio O, Yue L, Pepperberg DR, Thatcher GR

An NO donor approach to neuroprotective and procognitive estrogen therapy overcomes loss of NO synthase function and potentially thrombotic risk.

PloS one

VandeVrede L, Abdelhamid R, Qin Z, Choi J, Piyankarage S, Luo J, Larson J, Bennett BM, Thatcher GR

Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway.

BMC Pharmacology and Toxicology

Marton I Siklos, Ronak P Gandhi, Rui Xiong, Isaac T Schiefer, Vladislav Litosh, Lawren VandeVrede, Gregory RJ Thatcher

NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-ß neuropathology in transgenic models of Alzheimer’s disease.

BMC Pharmacology and Toxicology

Gregory RJ Thatcher, Jia Luo, Lawren VandeVrede, Zhihui Qin, Sue Lee, Ramy Abdelhamid, Brian M Bennett, Mary Jo LaDu, Leon Tai, John Larson

Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.

Journal of medicinal chemistry

Qin Z, Luo J, VandeVrede L, Tavassoli E, Fa' M, Teich AF, Arancio O, Thatcher GR

Mechanistic investigation of nitrate chimeras for Alzheimer's disease.

Alzheimer's & Dementia

Jia Luo, Lawren VandeVrede, Zhihui Qin, Ehsan Tavasolli, Gregory Thatcher

Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.

Journal of medicinal chemistry

Schiefer IT, VandeVrede L, Fa' M, Arancio O, Thatcher GR

Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent Mechanism.

ACS chemical neuroscience

Abdelhamid R, Luo J, Vandevrede L, Kundu I, Michalsen B, Litosh VA, Schiefer IT, Gherezghiher T, Yao P, Qin Z, Thatcher GR

Chapter 1: Seven New Species and a New Subgenus of Forest Mice (Rodentia: Muridae: Apomys) from Luzon Island.

Fieldiana Life and Earth Sciences

Lawrence R. Heaney, Danilo S. Balete, Eric A. Rickart, Phillip A. Alviola, Mariano Roy M. Duya, Melizar V. Duya, M. Josefa Veluz, Lawren VandeVrede, Scott J. Steppan